Bluebird Bio Reports No Evidence that LentiGlobin for Sickle Cell Causes AML
Bluebird Bio Says Cash Crunch Raises 'Going Concern' Risk - Bloomberg
bluebird bio | Pioneering Gene Therapies | Recode for Life
bluebird bio plans 'new nest' around hybrid work model
Bluebird Bio CEO defends $1.8 million price tag for new gene therapy
Bluebird Bio's Rare Disease Gene Therapies Recommended for FDA Approval
Nick Leschly, CEO of bluebird bio spinout 2seventy bio says 2023 will be a 'special year' - Boston Business Journal
Cambridge gene therapy firm bluebird bio to move to Somerville - Boston Business Journal
Low on cash, Bluebird Bio and its gene therapies face uncertain future
bluebird bio submits BLA for single-dose gene therapy to treat beta-thalassemia
Bluebird's Gene Therapy; Neurocrine-Sosei's Pact; Twist-Abveris's Deal
Bluebird Bio: Shares likely to suffer further dilution - Business News
bluebird bio (@bluebirdbio) / Twitter
PharmaShots Interview: bluebird bio's Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy
JPMorgan Day 3: Bluebird Bio preps for beti-cel launch
Bluebird Bio gene therapy wins first FDA approval for rare blood disorder - MedCity News
BlueBird Bio's 2-day reckoning is at hand - News - MM+M
bluebird bio completes spin-off of cell therapy company 2seventy bio | Seeking Alpha
Bluebirdbio hi-res stock photography and images - Alamy
Bluebird Bio has 'doubts' about continuing to do business through 2022, announces CFO resignation | Fierce Pharma
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
bluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) | Seeking Alpha
bluebird bio: One Of My Top Picks For 2021 (NASDAQ:BLUE) | Seeking Alpha
